Drug intelligence / Profile preview

slv-334

Development stage: Discontinued
Lead developer: Abbott
Modality: Small Molecules
Administration: Intravenous

Overview

SLV-334 is a small molecule drug initially developed for the treatment of nervous system diseases, particularly traumatic brain injury. It acts as an inhibitor of both endothelin-converting enzyme (ECE) and enkephalinase (neprilysin), which are involved in the regulation of neuropeptides and vasoactive peptides. The drug was originally developed by AbbVie and later investigated by Solvay Pharmaceuticals. Clinical development has been discontinued[2][3].

Other names: 1H-1-Benzazepine-1-acetic acid, 3-(((1-((2R)-2-carboxy-4-(1-naphthalenyl)butyl)cyclopentyl)carbonyl)amino)-[4]

Targets

NEP (Neutral Endopeptidase)ECE1 (Endothelin-converting enzyme 1)

Beyond the preview

Go deeper on slv-334.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on slv-334.

Explore the full profile